로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Antibody > IFN-gamma > IFN-M411

Monoclonal Anti-IFNγ Antibody, Human IgG1 (13E6H4)

  • Source

    Monoclonal Anti-IFNγ Antibody, Human IgG1 (13E6H4) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.

  • Clone

    13E6H4

  • Isotype

    Human IgG1/kappa

  • Conjugate

    Unconjugated

  • Antibody Type

    Recombinant Monoclonal

  • Reactivity

    Human

  • Immunogen

    Recombinant Human IFNγ derived from HEK293 cells.

  • Specificity

    This product is a specific antibody specifically reacts with IFN-γ, Human. No cross-reactivity is detected with other human cytokines, including IL-2, IL-4, IL-6, IL-10, GM-CSF and TNF-alpha.

  • Application
    ApplicationRecommended Usage
    ELISA0.1-100 ng/mL
  • Purity

    >95% as determined by SDS-PAGE.

  • Purification

    Protein A purified/ Protein G purified

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
IFN-gamma SDS-PAGE

Monoclonal Anti-IFNγ Antibody, Human IgG1 (13E6H4) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

Bioactivity-ELISA
 IFN-gamma ELISA

Immobilized Human IFN-gamma, premium grade (Cat. No. IFG-H4211) can bind Monoclonal Anti-IFNγ antibody, Human IgG1 (13E6H4) (Cat. No. IFN-M411) with a linear range of 0.09-1.56 ng/mL (QC tested). No cross-reactivity is detected with other human cytokines, including IL-2, IL-4, IL-6, IL-10, GM-CSF and TNF-alpha.

Bioactivity-SPR
 IFN-gamma SPR

Monoclonal Anti-IFNγ antibody, Human IgG1 (Cat. No. IFN-M411) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human IFN-gamma, premium grade (Cat. No. IFG-H4211) with an affinity constant of 0.158 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Bioactivity-BLI
 IFN-gamma BLI

Loaded Monoclonal Anti-IFNγ antibody, Human IgG1 (Cat. No. IFN-M411) on AHC Biosensor, can bind Human IFN-gamma, premium grade (Cat. No. IFG-H4211) with an affinity constant of 0.653 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

  • Background
    Interferon-gamma (IFN-γ/IFNG) is a dimerized soluble cytokine that is the only member of the type II class of interferon. This interferon was originally called macrophage-activating factor, a term now used to describe a larger family of proteins to which IFN-γ belongs. IFN-gamma has been used in a wide variety of clinical indications. Interferon-gamma (IFNgamma) is a central regulator of the immune response and signals via the Janus Activated Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) pathway. Interferon gamma has broader roles in activation of innate and adaptive immune responses to viruses and tumors, in part through upregulating transcription of genes involved in cell cycle regulation, apoptosis, and antigen processing/presentation. Despite this, rodent and human trophoblast cells show dampened responses to IFNG that reflect the resistance of these cells to IFNG-mediated activation of major histocompatibility complex (MHC) class II transplantation antigen expression.
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 450,000

가격(KRW) : 3,270,000

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs:3 Details
  • Number of Drugs in Clinical Trials:9 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

DMF 신청
DMF (Drug Master File)

관련 제품

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop